The startup offers a habit-building application that employs gamification and a team-based accountability system, where users collaborate in groups of five to foster routine development. This approach enhances user engagement and promotes skill acquisition, ultimately improving individual well-being.

AIRNA is developing RNA editing therapies to treat rare and common diseases by precisely modifying RNA sequences to correct genetic mutations. This approach aims to enhance patient health outcomes by targeting the underlying causes of genetic disorders.

Alivexis develops custom biopharmaceutical solutions through advanced genetic engineering and personalized medicine techniques, addressing the need for tailored therapies in the pharmaceutical industry. The company focuses on optimizing drug efficacy and safety by creating treatments that are specifically designed to meet individual patient profiles.

The startup develops drug delivery technology that enables the transport of therapeutic agents across the blood-brain barrier to target incurable neuronal diseases. This platform enhances the efficacy of treatments for patients suffering from central nervous system disorders by ensuring precise drug delivery.

The startup specializes in cell encapsulation technology that enhances the efficiency of cell mass production for engineering applications. This technology enables clients to utilize cells effectively across various domains, from research to clinical use, by providing a reliable method for handling and processing cells.

The startup has developed a drug discovery platform that utilizes plum-con analysis and semi-intact cell reseal technology to replicate the progression of pathological cells and analyze their protein networks over time. This approach enables researchers to identify and evaluate potential drug target molecules and new drug candidates more effectively.

Celsius Therapeutics develops precision medicines utilizing genomic and proteomic data to create targeted therapies for patients with cancer and autoimmune diseases. By focusing on the underlying biological mechanisms of these conditions, the company aims to improve treatment efficacy and patient outcomes.

Fast offers an online login and checkout solution that utilizes secure authentication protocols to enhance user data protection during transactions. This technology addresses the risk of data breaches and cart abandonment by streamlining the shopping experience for consumers.

Neusignal Therapeutics develops small-molecule therapeutics targeting Alzheimer's disease and other central nervous system disorders, utilizing proprietary signaling network insights to create novel compounds. The company addresses the unmet medical need for effective treatments that improve cognitive function and quality of life for patients suffering from dementia and psychiatric illnesses.

Global Vascular develops a drug-eluting stent delivery system utilizing nanotechnology to treat lower limb artery disease. This technology aims to improve blood flow and reduce the risk of thrombosis in patients suffering from ischaemia.

Mediphone provides specialized medical interpretation and translation services, utilizing AI-driven machine translation and a network of professional interpreters to facilitate communication between healthcare providers and foreign patients. This addresses the critical issue of language barriers in medical settings, ensuring accurate and timely patient care while enhancing the safety and efficiency of healthcare delivery.

Metagen Therapeutics utilizes microbiome science to develop fecal microbiota transplantation (FMT) therapies aimed at treating conditions such as ulcerative colitis and other microbiome-related diseases. By establishing a microbiome bank, the company enhances the accessibility and application of FMT, addressing the need for effective treatments in gastrointestinal health.

Purec develops culture technology that enhances the efficacy of treatment processes in healthcare. By optimizing microbial cultures, the company improves patient outcomes and reduces the time required for effective treatment.

reverSASP is a therapeutics company targeting the senescence-associated secretory phenotype (SASP) to develop treatments for age-related diseases. By focusing on this specific cellular mechanism, the company aims to mitigate the detrimental effects of cellular senescence on tissue function and overall health.

The startup develops antibody-based therapeutics that utilize engineered antibody seeds for the diagnosis and treatment of various cancers, including breast and ovarian cancer. By enhancing the efficacy of cancer drugs, the company aims to improve patient recovery rates and expand treatment options for oncologists.

Shinobi engineers immune evasive and armored induced pluripotent stem cells (iPSCs) to enhance cell therapy efficacy. Their technology shields iPSC-derived therapies from innate and antibody-mediated immune rejection, allowing them to function within the patient's immune system. This platform aims to unlock the full therapeutic potential of cell therapies across various disease indications.

The startup develops high-intensity focused ultrasound therapy systems that provide precise tissue targeting and real-time imaging for cancer treatment. This technology enhances treatment accuracy and patient comfort while addressing the limitations of traditional invasive surgical methods.

STORM Therapeutics is developing first-in-class small molecule therapies that target RNA modifying enzymes (RME) to create novel cancer treatments. By focusing on over 150 RNA modifications and approximately 300 RNA modifying enzymes, the company aims to address the limitations of current cancer therapies.

The startup develops genome analysis technology that enables contract testing and analysis services to detect minute quantities of bacteria in embryos by examining their genes and chromosomes. This technology helps identify genetic abnormalities before pregnancy, thereby alleviating physical and mental burdens for women.